May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...
AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year ...
AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...
Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. AZN to develop specialized ...
Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift ...
The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...
AstraZeneca AZN and AbbVie ABBV are leading U.S. drugmakers with strong positions in high-growth therapeutic areas like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results